BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2011

View Archived Issues

Intranasal PH-94B spray reduces anxiety in women with social anxiety disorder

Read More

GI-4000 is immunogenic in phase IIa consolidation therapy trial in stage I-III NSCLC

Read More

Promising preclinical data reported on new HIV vaccine based on lumpy skin disease virus

Read More

Amgen designs novel beta-secretase 1 inhibitors for cognition disorders

Read More

Bayer Schering Pharma presents new cancer diagnostic imaging agents

Read More

New melanocortin MC1 receptor agonists synthesized

Read More

Neuralstem cleared to dose final cohort in ongoing phase Ia NSI-189 trial

Read More

Threshold Pharmaceuticals completes enrollment in phase II TH-302 pancreatic cancer trial

Read More

Cel-Sci's anticancer drug Multikine lowers cholesterol in phase II trials

Read More

GC-33 is safe in hepatocellular carcinoma in first-in-human study

Read More

TriMix-DC vaccine is safe and immunogenic in phase I trial in pretreated melanoma

Read More

Algeta receives grant to develop novel tumor-targeted thorium conjugates

Read More

MicroRNA-155 may be a marker of metabolic syndrome

Read More

New antibacterial FabI inhibitors synthesized by FAB Pharma

Read More

Yissum Research Development patents new cannabinoid CB2 receptor ligands

Read More

Seaside Therapeutics begins phase IIb STX-209 trial in autism spectrum disorders

Read More

Luminex to acquire EraGen Biosciences

Read More

Merck KGaA discontinues approval process for cladribine tablets in MS

Read More

Abbott and Biotest enter agreement to develop and commercialize BT-06 for autoimmune diseases

Read More

FDA approves CorMedix's SPA for phase III CRMD-001 trial

Read More

Achillion begins dosing in second segment of phase IIa ACH-1625 trial in chronic hepatitis C

Read More

Infinity Pharmaceuticals expands development program for anticancer agent IPI-926

Read More

Ligand Pharmaceuticals to advance Captisol-enabled melphalan program

Read More

NanoBio starts phase Ib trial of intranasal influenza vaccine

Read More

FDA approves personalized cell therapy laViv to improve appearance of smile lines

Read More

Enrollment begins in phase II RP-G28 trial in patients with lactose intolerance

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing